IFRX Projected Dividend Yield
Ord/InflaRx NV ( NASDAQ : IFRX )InflaRx is a clinical-stage biopharmaceutical company focused on applying its anti-C5a technology to discover and develop specific inhibitors of the complement activation factor known as C5a. C5a is an inflammatory mediator involved in the progression of a variety of autoimmune and other inflammatory diseases. Co.'s primary product candidate, vilobelimab, is an intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in various clinical settings. Co. develops vilobelimab for the treatment of Hidradenitis Suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. 20 YEAR PERFORMANCE RESULTS |
IFRX Dividend History Detail IFRX Dividend News IFRX Competitors News |
Year | Declaration Date | Ex-Dividend Date | Record Date | Payable Date | Dividend $ Amount |
Total: | 0.0000 |